Polymorphisms of drug-metabolizing enzymes and transporters contribute to the individual variations of erlotinib steady state trough concentration, treatment …
D Liao, Z Liu, Y Zhang, N Liu, D Yao, L Cao… - Frontiers in …, 2020 - frontiersin.org
Background Erlotinib is presently the first line treatment for non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing …
(NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing …
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
PURPOSE: Genetic variations in EGFR may alter protein function and therefore the
therapeutic efficacy of epidermal growth factor receptor inhibitors. This study investigated the …
therapeutic efficacy of epidermal growth factor receptor inhibitors. This study investigated the …
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib
E Giovannetti, PA Zucali, GJ Peters, F Cortesi… - Molecular cancer …, 2010 - AACR
EGFR mutations are strongly predictive of epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitor activity in non–small cell lung cancer (NSCLC), but resistance mechanisms …
kinase inhibitor activity in non–small cell lung cancer (NSCLC), but resistance mechanisms …
EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts)
VM Villaflor, L Buckingham, M Gale, J Coon… - Journal of Clinical …, 2005 - ascopubs.org
7077 Background: Activating mutations in exons 18–21 of the EGFR gene have been found
in tumors from NSCLC pts that respond to gefitinib (GEF). The goal of this study was to …
in tumors from NSCLC pts that respond to gefitinib (GEF). The goal of this study was to …
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial
JY Douillard, FA Shepherd, V Hirsh, T Mok… - Journal of clinical …, 2010 - ascopubs.org
Purpose In the phase III INTEREST trial, 1,466 pretreated patients with advanced non–small
cell lung cancer (NSCLC) were randomly assigned to receive gefitinib or docetaxel. As a …
cell lung cancer (NSCLC) were randomly assigned to receive gefitinib or docetaxel. As a …
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert… - Journal of clinical …, 2011 - ascopubs.org
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib
L Zhang, X Yuan, Y Chen, XJ Du, S Yu, M Yang - Gene, 2013 - Elsevier
AIM: As a novel molecularly targeting agent for non-small-cell lung cancer (NSCLC),
Gefitinib can block its tyrosine kinase activity of the epidermal growth factor receptor (EGFR) …
Gefitinib can block its tyrosine kinase activity of the epidermal growth factor receptor (EGFR) …
Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)
J Douillard, V Hirsh, TS Mok, MA Socinski… - Journal of Clinical …, 2008 - ascopubs.org
8001 Background: In INTEREST, gefitinib demonstrated non-inferior overall survival (OS),
more favorable tolerability and improved QoL vs docetaxel in advanced pretreated NSCLC …
more favorable tolerability and improved QoL vs docetaxel in advanced pretreated NSCLC …
[HTML][HTML] Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
M Tiseo, M Capelletti, G De Palma, V Franciosi… - Journal of Thoracic …, 2008 - Elsevier
Introduction Epidermal growth factor receptor (EGFR) gene intron 1 contains a polymorphic
single sequence dinucleotide repeat (CA) n whose length has been found to inversely …
single sequence dinucleotide repeat (CA) n whose length has been found to inversely …
[HTML][HTML] Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer
Y Nakamura, K Sano, H Soda, H Takatani… - Journal of thoracic …, 2010 - Elsevier
Introduction We assessed the relationship between the plasma concentration of gefitinib and
its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC) …
its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC) …